Clinical Trials Browser

Enrolling by invitation × nimotuzumab × Gastrointestinal × Clear all

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma